The Canadian Nuclear Safety Commission has given Bruce Power approval to operate the company’s hot cell facility in Tiverton, Ontario, for medical radioisotope processing. This approval allows the facility to conduct Target Carrier Removal (TCR), a key step in the production of lutetium-177, an isotope used to treat prostate and gastric cancers.